A lot is unknown about ALS which is why the Penn Comprehensive ALS Center is committed to researching causes, therapies and cutting-edge treatments.
Penn Medicine belongs to the NEALS (Northeast ALS Consortium), the largest ALS research group in the United States. Members of our group routinely attend and present at national and international ALS conferences.
Through our research and clinical trials, we hope to:
- Slow down the progression of ALS
- Evaluate new technologies to improve care of patients with ALS
- Improve our understanding of ALS
See All ALS Clinical Trials
ALS Research Highlights
The Penn Medicine ALS team is always looking to the future for ALS care. Our multi-disciplinary team is passionate about finding the next treatment to help our patients. Explore a selection of recent findings in which our team participated.
Healey Platform Trial
Focused around finding answers quickly for patients the Healey Platform Trial, lets us test new therapies fast and gives participants a greater chance of receiving an active study drug. New therapies are frequently evaluated for inclusion in the Healey Platform Trial and we are happy to discuss new trial opportunities.
Targeted Genetic Trials
Penn has the unique resources necessary to participate in clinical trials targeted towards specific genetic variants that can cause ALS. Recent efforts have included the VALOR trial targeting SOD1 mutations and the ALSpire trial targeting ataxin-2 mutations.
The Phenotype, Genotype & Biomarkers in ALS and Related Disorders (PGB) Study
As a member of the Clinical Research in ALS and Related Disorders for Therapeutic Development (CReATe) Consortium, we participate in studies like the PGB study, which are designed to advance our knowledge of ALS to improve future therapies and diagnostic methods.
Collaborating Penn Research Centers
Donate to Penn Comprehensive ALS Center Research Efforts